Seres Therapeutics (MCRB) Downgraded to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of Seres Therapeutics (NASDAQ:MCRB) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

MCRB has been the topic of a number of other research reports. Oppenheimer set a $16.00 target price on Seres Therapeutics and gave the company a buy rating in a research note on Friday, November 9th. Chardan Capital reiterated a buy rating on shares of Seres Therapeutics in a report on Sunday, October 28th. ValuEngine lowered Seres Therapeutics from a hold rating to a sell rating in a report on Monday, September 17th. Cantor Fitzgerald reiterated an overweight rating on shares of Seres Therapeutics in a report on Friday, November 23rd. Finally, BidaskClub lowered Seres Therapeutics from a hold rating to a sell rating in a report on Thursday, December 13th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $13.06.

Shares of MCRB traded up $0.17 during mid-day trading on Wednesday, reaching $6.38. 73,266 shares of the company’s stock traded hands, compared to its average volume of 98,175. The stock has a market cap of $244.32 million, a price-to-earnings ratio of -2.89 and a beta of 1.44. Seres Therapeutics has a 12 month low of $4.42 and a 12 month high of $11.35.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.03. The firm had revenue of $9.06 million for the quarter, compared to analysts’ expectations of $23.43 million. Seres Therapeutics had a negative return on equity of 1,584.66% and a negative net margin of 515.16%. As a group, sell-side analysts expect that Seres Therapeutics will post -2.58 EPS for the current year.

In related news, insider John G. Aunins sold 14,279 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $5.94, for a total value of $84,817.26. Following the completion of the sale, the insider now owns 103,811 shares in the company, valued at $616,637.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John G. Aunins sold 14,282 shares of the business’s stock in a transaction that occurred on Monday, December 17th. The shares were sold at an average price of $6.39, for a total value of $91,261.98. Following the completion of the sale, the insider now owns 75,250 shares of the company’s stock, valued at approximately $480,847.50. The disclosure for this sale can be found here. 37.10% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Paloma Partners Management Co purchased a new stake in shares of Seres Therapeutics in the third quarter valued at approximately $147,000. Jefferies Group LLC lifted its holdings in Seres Therapeutics by 75.5% during the third quarter. Jefferies Group LLC now owns 21,424 shares of the biotechnology company’s stock worth $163,000 after buying an additional 9,215 shares during the period. Citadel Advisors LLC lifted its holdings in Seres Therapeutics by 48.0% during the third quarter. Citadel Advisors LLC now owns 31,400 shares of the biotechnology company’s stock worth $239,000 after buying an additional 10,183 shares during the period. Bank of America Corp DE lifted its holdings in Seres Therapeutics by 175.0% during the second quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock worth $314,000 after buying an additional 23,222 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Seres Therapeutics by 18.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 117,255 shares of the biotechnology company’s stock worth $1,009,000 after buying an additional 18,562 shares during the period. Hedge funds and other institutional investors own 78.35% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Recommended Story: 52-Week High/Low

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply